Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Market Closed 08-14 16:00:00 EDT

0.6799

+0.0089

+1.33%

盘后0.6838

+0.0039+0.58%

19:34 EDT

High0.6953	Low0.6573	Vol15.79K
Open0.6890	D1 Closing0.6710	Amplitude5.66%
Mkt Cap8.56M	Tradable Cap5.18M	Total Shares12.59M
T/O10.67K	T/O Rate0.21%	Tradable Shares7.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.6799,"timestamp":1786737600000,"preClose":0.671,"halted":0,"volume":15789,"hourTrading":{"tag":"盘后","latestPrice":0.683846,"preClose":0.6799,"latestTime":"19:34 EDT","volume":1050,"amount":716.875846,"timestamp":1786750444729,"change":0.003946,"changeRate":0.005804,"amplitude":0.005804},"delay":0,"changeRate":0.013263785394932798,"floatShares":7613900,"shares":12591099,"eps":-0.94,"marketStatus":"Market Closed","change":0.0089,"latestTime":"08-14 16:00:00 EDT","open":0.689,"high":0.6953,"low":0.6573,"amount":10668.763874850001,"amplitude":0.056632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.94,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.671,"preHourTrading":{"tag":"盘前","latestPrice":0.68,"preClose":0.671,"latestTime":"08:58 EDT","volume":85,"amount":58.000804,"timestamp":1786712304780,"change":0.009,"changeRate":0.013413,"amplitude":0.147243},"postHourTrading":{"tag":"盘后","latestPrice":0.683846,"preClose":0.6799,"latestTime":"19:34 EDT","volume":1050,"amount":716.875846,"timestamp":1786750444729,"change":0.003946,"changeRate":0.005804,"amplitude":0.005804},"volumeRatio":0.5521285776217902,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE/wiki","defaultTab":"wiki","newsList":[{"id":"2659167963","title":"Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167963","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167963?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:25","pubTimestamp":1786652704,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Q2 net loss widens on higher R&D costsOverviewUS biotech firm's Q2 net loss widened yr/yr on higher R&D expensesCompany completed Cy Biopharma acquisition post-quarter, adding CY20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505","APRE","ENSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156740","title":"Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156740?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:16","pubTimestamp":1786619767,"startTime":"0","endTime":"0","summary":"Pyxis Oncology Q2 loss widens on increased administrative costsOverviewUS cancer therapeutics developer's Q2 net loss widened yr/yr as operating expenses roseCompany completed $50 mln private placemen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","APRE","IMNM","BK4139","CRDF","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659990044","title":"Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659990044","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659990044?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:22","pubTimestamp":1786566165,"startTime":"0","endTime":"0","summary":"Longeveron Q2 net loss widens on higher legal, clinical trial costsOverviewUS biotech firm's Q2 revenue fell 10% yr/yr, mainly due to lower contract manufacturing incomeNet loss for Q2 widened 22% yr/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44911Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","OLMA","BK4505","SPRB","LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658088309","title":"Aprea Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658088309","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658088309?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:24","pubTimestamp":1786541089,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAprea Therapeutics IncAPRE.OQreported a quarterly adjusted loss of 7 cents per share for the quarter ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970424","title":"LiveWorld Q2 Net Loss Widens on Higher Operating Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970424","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970424?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:10","pubTimestamp":1786540207,"startTime":"0","endTime":"0","summary":"LiveWorld Q2 net loss widens on higher operating costsOverviewAI-powered intelligence systems firm's Q2 revenue grew 9% yr/yr, driven by healthcare segmentCompany posted Q2 net loss from operations of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4608","PHUN","BK4539","BK4139","SMWB","APRE","BK4516","BK4023","LVWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977651","title":"Aprea Therapeutics Q2 EPS USD -0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977651?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:31","pubTimestamp":1786537864,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXH9GCNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658497759","title":"Aprea Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658497759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658497759?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:30","pubTimestamp":1786537802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUAN9FHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951980","title":"Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951980","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951980?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:33","pubTimestamp":1786393980,"startTime":"0","endTime":"0","summary":"HEADLINESBarrick Mining Settles Newmont Nevada Dispute for $1.95 Billion, Clearing Way to List its Gold AssetsBarrick Mining has settled a long-standing dispute with rival Newmont over their Nevada op","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","SLAB","IMNN","REFI","BSIN","LVWD","JBI","IE00B3S45H60.SGD","MASS","BK4179","ACCS","STIM","HBIO","VSTS","AMTM","BK4175","CAH","VERA","LU0154236417.USD","BK4123","RXT","SLSN","BK4023","FLOC","NVRI","LU0240877869.USD","BK4109","SYPR","OBIO","ARMK","DOMH","DRIO","GHI","MIDD","SG9999001440.SGD","TCRX","BK4127","MEMS","BK4167","CRIS","KLXE","MEDI","AVXL","IMUX","WHF","CANC","LEGN","TNGX","BWEN","PESI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657476196","title":"Aprea Therapeutics Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657476196","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657476196?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:48","pubTimestamp":1786117685,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc <APRE.OQ> expected to post a loss of23cents a share - Earnings PreviewAprea Therapeutics IncAPRE.OQAPRE.Ois expected to  show a rise in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683675","title":"Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683675","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657683675?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:30","pubTimestamp":1785861019,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. ($APRE) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. (APRE) has completed a Phase 1/2a st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apreas-atrn-119-trial-completion-what-it-means-for-apre-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apreas-atrn-119-trial-completion-what-it-means-for-apre-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE","ISBC","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655436872","title":"Aprea Therapeutics Targets Q4 2026 Clinical Data Readout for Apr-1051 Phase 1 Acesot-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655436872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655436872?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:10","pubTimestamp":1785413414,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trialAprea outlined plans to accelerate enrollment in its Phase 1 ACESOT-1051 dose-escalation trial of WEE1 in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6FQZ2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","BK4139","APRE","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874761","title":"Aprea Therapeutics - Acesot-1051 Enrollment Accelerating to 6-10 Patients Per Month by Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874761?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874750","title":"Aprea Therapeutics - Dose Escalation and Backfill Expansion Expected to Complete in Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874750?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874721","title":"Aprea Therapeutics - to Enroll at Least 50 Patients with Usc or Cyclin E-Overexpressing Proc","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874721?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655747518","title":"Aprea Therapeutics Provides Acesot-1051 Program Update for Wee1 Inhibitor Apr-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655747518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655747518?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687473","title":"Aprea Therapeutics - Advances Apr-1051 in Usc, Proc, and Combination Regimens in Head and Neck, Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687473?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587475","title":"Aprea Therapeutics - Acesot-1051 Clinical Sites Expand from Three to Ten","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655587475?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775446","title":"Aprea Therapeutics Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653775446?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:27","pubTimestamp":1784838452,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics gets Nasdaq extension to regain $1 minimum bid price complianceAprea Therapeutics received a Nasdaq notice granting a second 180-day window to regain $1 minimum bid-price compliance","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL2rxdRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644072977","title":"Aprea Therapeutics shareholders elect three Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644072977","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644072977?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:16","pubTimestamp":1781727385,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics held its annual shareholder meeting on June 16, 2026.Investors approved a charter amendment authorizing the board to carry out a reverse stock split.If implemented, the reverse split ratio can range from 1-for-3 to 1-for-8, with any fractional shares rounded up.Shareholders ratified EisnerAmper as the independent registered public accounting firm for the 2026 fiscal year.Shareholders selected a non-binding advisory vote to hold future say-on-pay votes every year.An adjournment proposal was adopted to allow more time to solicit votes if needed to secure support for the reverse stock split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLSP81m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640088959","title":"Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640088959","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640088959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:06","pubTimestamp":1780315579,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics presented updated Phase 1 results for WEE1 inhibitor APR-1051 at ASCO 2026 on May 30.Early data showed signs of tumor shrinkage in some endometrial cancer patients, with disease control in additional heavily pretreated solid tumors.Side effects were described as manageable, supporting continued dose escalation and a path toward selecting a later-stage dose.The trial is expanding enrollment into uterine serous carcinoma, with a separate expansion in platinum-resistant ovarian cancer.Dose escalation and backfill expansion are expected to complete in Q2 2027, setting up potential Phase 2 planning.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4yct9f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","APRE","SG9999014005.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014039.USD","NDAQ","BK4112"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":0.0455},{"period":"1month","weight":-0.0257},{"period":"3month","weight":-0.269},{"period":"6month","weight":0.1157},{"period":"1year","weight":-0.5977},{"period":"ytd","weight":-0.2029}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.117728},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.094212},{"month":6,"riseRate":0.285714,"avgChangeRate":0.005319},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.070517},{"month":8,"riseRate":0.428571,"avgChangeRate":0.009327},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}